AKR1C3在评估直肠癌放化疗早期疗效的应用价值

摘要
图/表
参考文献(22)
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探究醛固酮类还原酶家族1 成员C3（AKR1C3）在评估直肠癌放化疗早期疗效的应用价值。方法回顾性分析2013年1月～2020年1月于粤北人民医院进行放化疗的60例直肠癌患者的临床资料，使用免疫组化检测法对患者病理标本中AKR1C3表达水平进行检测，使用Logistic多元回归分析对AKR1C3 应用价值进行研究。结果放化疗抵抗组共40例，放化疗敏感组共20例。放化疗抵抗组患者的AKR1C3表达程度高于放化疗敏感组，差异有统计学意义（P＜0.05）。不同性别、分化程度、病变长度、AKR1C3表达患者的放化疗抵抗发生率比较，差异有统计学意义（P＜0.05）。AKR1C3 高表达是影响直肠癌患者放化疗早期疗效的危险因素（P＜0.05）。结论 AKR1C3可能为适用于直肠癌患者放化疗疗效判定的一项敏感性指标，从而有效改善患者的预后。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	崔磊
	徐晓南
	曾星
	孙俊旗
	高双全
	苗淑红

关键词 ： AKR1C3, 直肠癌, 放疗, 化疗, 疗效

Abstract：Objective To explore the application value of aldosterone reductase family 1 member C3 (AKR1C3) in evaluating the early efficacy of radiotherapy and chemotherapy for rectal cancer.Methods The clinical data of 60 patients with rectal cancer treated by radiotherapy and chemotherapy in Yuebei People′s Hospital from January 2013 to January 2020 were retrospectively analyzed.The expression level of AKR1C3 in pathological specimens was detected by immunohistochemistry,and the application value of AKR1C3 was studied by Logistic multiple regression analysis.Results There were 40 cases in chemoradiotherapy resistance group and 20 cases in chemoradiotherapy sensitive group.The expression of AKR1C3 in chemoradiotherapy resistant group was higher than that in chemoradiotherapy sensitive group,and the difference was statistically significant (P＜0.05).There was statistically significant difference in the incidence of radiotherapy and chemotherapy resistance in patients with different gender,degree of differentiation,length of lesion,and AKR1C3 expression (P＜0.05).The high expression of AKR1C3 was a risk factor affecting the early efficacy of radiotherapy and chemotherapy in patients with rectal cancer (P＜0.05).Conclusion AKR1C3 may be used as a sensitive index to evaluate the efficacy of radiotherapy and chemotherapy in patients with rectal cancer,so as to effectively improve the prognosis of patients.

Key words： AKR1C3 Rectal cancer Radiotherapy Chemotherapy Curative effect

基金资助:广东省韶关市科技计划项目（2018sn023、2019sn 007）；广东省韶关市卫生计生科研项目（Y18028、Y19001）

引用本文:

崔磊；徐晓南；曾星；孙俊旗；高双全；苗淑红. AKR1C3在评估直肠癌放化疗早期疗效的应用价值[J]. 中国当代医药, 2020, 27(35): 160-163.
CUI Lei；XU Xiao-nan；ZENG Xing；SUN Jun-qi； GAO Shuang-quan； MIAO Shu-hong. Application value of AKR1C3 in evaluating the early efficacy of radiotherapy and chemotherapy for rectal cancer. 中国当代医药, 2020, 27(35): 160-163.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2020/V27/I35/160